TY - JOUR T1 - When a Parkinson’s disease patient starts to hallucinate JF - Practical Neurology JO - Pract Neurol SP - 238 LP - 241 DO - 10.1136/jnnp.2008.152579 VL - 8 IS - 4 AU - W Poewe Y1 - 2008/08/01 UR - http://pn.bmj.com/content/8/4/238.abstract N2 - Visual hallucinations are a typical feature of Lewy body parkinsonism and occur in some 40% of patients with Parkinson’s disease. Age and cognitive decline are the most important intrinsic risk factors, but hallucinosis is often triggered by comorbid conditions such as infection and dehydration. The single most important trigger, however, is exposure to CNS drugs, in particular antiparkinsonian agents. While hallucinosis and psychosis can be triggered by amantadine and anticholinergics, they are more commonly experienced after changes in dopaminergic medication. Dopamine agonists have greater potential to induce hallucinosis compared with L-dopa. Attempting to reduce antiparkinsonian drugs is an important part in the management of these patients, but atypical neuroleptics like clozapine or quetiapine are frequently necessary. Visual hallucinations in Parkinson’s disease patients with dementia can also be improved by treatment with the cholinesterase inhibitor rivastigmine. ER -